Rubius Therapeutics Company

Rubius has developed the technology to grow, genetically engineer and mature long-circulating Red-Cell Therapeutics.

Founded Date: 2013-01-01
Last Funding Type: Post-IPO Equity
Headquarters: Cambridge, Massachusetts, United States
Investors Number: 1
Employee Number: 101-250
Industry: Atrificial Vectors and Immune Cells
Estimated Revenue: $10M to $50M
Last Funding Date: 2021-03-17
Funding Status: IPO
Total Funding: 445000000